$ONVO News

Last published 1y ago

1y agoONVO VIVSVivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketGlobeNewswireSAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will
1y agoONVOVivoSim to Carry Forward Organovo 3D BioprintingGlobeNewswireSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (the "Company") announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change
1y agoONVOOrganovo Provides Update on Cash and Nasdaq Continued Listing RequirementsGlobeNewswireSAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory
1y agoLLY ONVOOrganovo Provides Business UpdateGlobeNewswireSAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory
1y agoLLY ONVOOrganovo Announces Close of the Sale of FXR Program to Eli Lilly and CompanyGlobeNewswireSAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory
1y agoONVOOrganovo Announces Reverse Stock SplitGlobeNewswireSAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today
1y agoGRCE MTNB ONVOMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireBEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of
1y agoONVOOrganovo Announces the Issuance of Additional Shares in Conjunction with Warrant ExercisesGlobeNewswireSAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory
1y agoLLY ONVOOrganovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and CompanyGlobeNewswireSAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory
1y agoONVOOrganovo Announces Appointment of Norman Staskey as Chief Financial OfficerGlobeNewswireSAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
1y agoONVOOrganovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver MeetingGlobeNewswireSAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
1y agoONVOOrganovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver DiseasesGlobeNewswireSAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
2y agoONVOOrganovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative ColitisGlobeNewswireSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
2y agoONVOOrganovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseGlobeNewswireSAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
2y agoONVOOrganovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)GlobeNewswireSAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including
2y agoONVOOrganovo Holdings, Inc. Announces Pricing of $5.25 Million Public OfferingGlobeNewswireSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on
2y agoONVOOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboGlobeNewswireSAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in
2y agoONVOOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis CongressGlobeNewswireSAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis,
2y agoONVOOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis CongressGlobeNewswireSAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative
2y agoONVOOrganovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsGlobeNewswireSAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease
3y agoONVOOrganovo Highlights FXR314 Combination Therapy Potential and PlanGlobeNewswireSAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease
3y agoONVOOrganovo to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in
3y agoONVOOrganovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataGlobeNewswireSAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in
3y agoONVOOrganovo Announces FXR ProgramGlobeNewswireSAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high
3y agoONVOOrganovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn's Disease Drug CandidatesGlobeNewswireSAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies
4y agoONVOOrganovo to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith
4y agoONVOOrganovo Announces Postponement of Annual Meeting of StockholdersGlobeNewswireSAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the "Company"), today annou
4y agoONVOOrganovo Achieves 3D Tissue Model for Crohn's DiseaseGlobeNewswireSAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces th
4y agoONVOOrganovo, Inc. vs BICO Group AB - AIA Trial, Settlement before InstitutionUS Patent Trial and Appeal Board
4y agoONVOOrganovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting PatentsGlobeNewswireSAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo's foundational patent portfolio in 3D bioprinti
4y agoONVOOrganovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), today announced that it has granted a stock option to purchase 50,000 shares of common stock to one new employee. The stock option was granted pursuant to
4y agoONVOOrganovo Welcomes New Sr. Vice President of Strategy and Business DevelopmentGlobeNewswireSAN DIEGO, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, today announced the hiring of Curtis Tyr
4y agoONVOOrganovo Guides on Patent Portfolio and Successful IPR Defense of Two PatentsGlobeNewswireSAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), today announced that two of its patents have withstood a patent challenge, and the company provided guidance on how it expects to leverage its strong patent portfolio.
4y agoONVOOrganovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInkGlobeNewswireSAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), today released its first detailed response to the lawsuit Cellink (NASDAQ Stockholm: BICO) filed against it in Delaware court in 2021. At issue in this lawsuit is wheth
4y agoONVOOrganovo, Inc. vs Cellink AB - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
4y agoONVOOrganovo, Inc. vs Cellink AB - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
4y agoONVOOrganovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022GlobeNewswireSAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), today provided a business overview and progress update, and announced it is on track to establish its first models of inflammatory bowel disease in 2022 using its 3D bi
5y agoONVOOrganovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of QuorumGlobeNewswireSOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), today announced that the Company's annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business bein
5y agoONVONew patent granted for: Engineered Renal Tissues, Arrays Thereof, and Methods of Making the SameUS Patent Applications (USPTO)Disclosed are renal tissues and arrays thereof that include a layer of renal interstitial tissue, the renal interstitial tissue comprising renal fibroblasts and endothelial cells; and a layer of renal epithelial tissue, the renal epithelial tissue comprising renal tubular epithelial cells, the renal epithelial tissue in contact with the layer of renal interstitial tissue to form a three-dimensiona ...
5y agoONVOOrganovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)GlobeNewswireSOLANA BEACH, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced it will be featured as a presenting company at the H.C. Wainwright Global Life...
5y agoINFO NTLA ONVO CGENCathie Wood’s Power in Some Stocks Is Even Bigger Than It SeemsBloombergA rough week for Cathie Wood is reminding Wall Street that Ark Investment Management has a lot of cash in not that many companies. In fact, the firm’s dominance in some stocks may be even greater than it seems.
6y agoONVOOrganovo Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireSAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (“Organovo” or the “Company”) (Nasdaq: ONVO) announced today that it has regained compliance with the minimum bid price...
6y agoONVOOrganovo Announces One-for-Twenty Reverse Stock SplitGlobeNewswireSAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (the “Company”) (Nasdaq: ONVO) today announced that it filed a certificate of second amendment to its certificate of...
6y agoONVONew patent application published for: Platform for Engineered Implantable Tissues and Organs and Methods of Making the SameUS Patent Applications (USPTO)( 1 of 1 )
6y agoONVONew patent application published for: Multilayered Vascular TubesUS Patent Applications (USPTO)( 1 of 1 )
6y agoONVOTarveda Therapeutics Provides Update on Proposed Merger with OrganovoBusiness WireWATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the proposed merger agreement with Organovo Holdings, In ...
6y agoONVOOrganovo Announces Termination of Merger Agreement with Tarveda TherapeuticsBusiness WireSAN DIEGO--(BUSINESS WIRE)--Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) announced today that it has terminated the merger agreement with Tarveda Therapeutics, Inc. (“Tarveda”), originally announced on December 16, 2019, and will continue to operate as an independent company. The Company had submitted the merger proposal and other related proposals to be voted upon at a Special Meeting of S ...
6y agoONVOOrganovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda TherapeuticsGlobeNewswireBelieves Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination Encourages Board of Directors to Heed Investor Feedback and Re-Focus...
6y agoONVOOrganovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of StockholdersBusiness WireSAN DIEGO--(BUSINESS WIRE)--Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders (the “Special Meeting”) and then adjourned the Special Meeting until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposals Nos. 1 and 4. Organovo Proposal No. 1 is ...
6y agoONVOOrganovo Holdings, Inc. Announces Adjournment of Special Meeting of StockholdersBusiness WireSAN DIEGO--(BUSINESS WIRE)--Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) convened, on March 26, 2020, the special meeting of stockholders and then adjourned the special meeting of stockholders until Tuesday, April 7, 2020 10:00 A.M. Pacific Time at www.virtualshareholdermeeting.com/ONVO2020 to solicit additional proxies for Organovo Proposal Nos. 1 and 4. Organovo Proposal No. 1 is to appro ...